Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY2484595 in Japanese Subjects

Phase 2

Completed

Conditions: Dyslipidemias

Interventions: Drug: LY2484595
Drug: Placebo
Drug: Atorvastatin

First Posted Date: 2011-06-17

Last Posted Date: 2018-10-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 165

Registration Number: NCT01375075

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of LY2216684 in Healthy Females

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: LY2216684
Drug: Ortho Cyclen
Drug: Placebo

First Posted Date: 2011-06-15

Last Posted Date: 2018-10-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01373931

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Lantus
Drug: LY2963016

First Posted Date: 2011-06-15

Last Posted Date: 2014-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT01374178

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Phase 1

Completed

Conditions: Neoplasms
Neoplasm Metastasis
Pancreatic Cancer

Interventions: Drug: Galunisertib
Drug: Placebo
Drug: Gemcitabine

First Posted Date: 2011-06-14

Last Posted Date: 2018-05-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 170

Registration Number: NCT01373164

Locations: 🇺🇸
Florida Hospital Tampa HPG and Foregut Surgery, Tampa, Florida, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

and more 1 locations

Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: LY2584702 Reference Formulation
Drug: Placebo
Drug: LY2584702 Test Formulation

First Posted Date: 2011-06-13

Last Posted Date: 2019-01-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT01372085

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study of LY2216684 in Participants With Major Depression Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: SSRI

First Posted Date: 2011-06-10

Last Posted Date: 2018-10-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 288

Registration Number: NCT01370499

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

Phase 2

Completed

Conditions: Muscular Atrophy

Interventions: Drug: LY2495655
Drug: Placebo

First Posted Date: 2011-06-09

Last Posted Date: 2018-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 400

Registration Number: NCT01369511

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2886721

First Posted Date: 2011-06-07

Last Posted Date: 2019-09-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT01367262

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: LY2603618
Drug: Desipramine
Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2011-05-24

Last Posted Date: 2018-10-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01358968

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States

A Study of LY2881835 in Healthy People and People With Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY2881835

First Posted Date: 2011-05-24

Last Posted Date: 2019-06-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT01358981

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy